NEW YORK, July 13, 2022 /PRNewswire/ — The “Migraine Therapeutics Market – Competitive Analysis, Market Dynamics, Impact of COVID-19, Five Force Analysis” report has been added to Technavio’s offering. The migraine therapeutics market size is expected to increase by USD 1.06 billion, at a CAGR of 5.3% from 2020 to 2025. 38% of the market’s growth will originate from North America during the forecast period. The US is the key market for migraine therapeutics market in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia. The rising healthcare expenditure will facilitate the migraine therapeutics market growth in North America over the forecast period.
Enclose successful business strategies with detailed information on each region – Request a sample now!
The migraine therapeutics market is fragmented and the vendors are deploying growth strategies such as product launches to compete in the market. The migraine therapeutics market report includes information on the product launches, sustainability, and prospects of leading vendors including AbbVie Inc., Amgen Inc., Eli Lilly and Co., eNeura Inc., GlaxoSmithKline Plc, Grunenthal GmbH, H. Lundbeck AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories LLC. This statistical study of the migraine therapeutics market encompasses successful business strategies deployed by the key vendors.
- AbbVie Inc. – The company provides acute treatment for Migraine with or without Aura in adults, under the brand name UBRELVY.
- Amgen Inc. – The company provides treatment for Migraine under the brand name Aimovig.
- Eli Lilly and Co. – The company provides acute treatment for Migraine under the brand name REYVOW.
- eNeura Inc. – The company provides acute and prophylactic treatment of migraine headaches in adolescents (age 12 and older) and adults under the brand name sTMS mini.
- GlaxoSmithKline Plc – The company provides treatment for Migraine under the brand name Excedrin.
- To gain access to more vendor profiles with their key offerings available with Technavio – Click Now!
- Drivers: The market is driven by factors such as the increase in the number of patients suffering from migraine, rising advances in migraine therapeutics, and the rise in the number of approvals for preventive drugs for migraine.
- Challenges: The concerns related to the side effects of migraine drugs is hindering the market growth.
The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge. This migraine therapeutics market analysis report also provides detailed information on other upcoming trends that will have a far-reaching effect on the market growth.
Refine your marketing strategies by knowing more about drivers & challenges – Request a sample report now!
The competitive scenario provided in the migraine therapeutics market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
- By Product, the market is classified into drugs and devices.
- By Treatment, the market is classified into preventive treatment and abortive treatment.
- By Geography, the market is classified as North America, Europe, Asia, and ROW.
To know about the accurate prediction of the contribution of all the segments – Grab a sample!
- The protein therapeutics market share is expected to increase by USD 115.12 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 8.08%.
- The biologic therapy market share is expected to increase by USD 226.61 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 11%.
|
Migraine Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.3% |
|
Market growth 2021-2025 |
USD 1.06 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
4.82 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 38% |
|
Key consumer countries |
US, Germany, France, UK, and Japan |
|
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
|
Companies profiled |
AbbVie Inc., Amgen Inc., Eli Lilly and Co., eNeura Inc., GlaxoSmithKline Plc, Grunenthal GmbH, H. Lundbeck AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories LLC |
|
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
|
Customization purview |
If our report has not included the data you are looking for, you can reach out to our analysts and get customized segments. |
Table of Content
1 Executive Summary
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 01: Parent market
- 2.2 Market characteristics
- Exhibit 02: Market characteristics
- 2.3 Value chain analysis
- Exhibit 03: Value chain analysis: Pharmaceuticals market
3 Market Sizing
- 3.1 Market definition
- Exhibit 04: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 05: Market segments
- 3.3 Market size 2020
- 3.4 Market outlook: Forecast for 2020 – 2025
- Exhibit 06: Global – Market size and forecast 2020 – 2025 ($ million)
- Exhibit 07: Global market: Year-over-year growth 2020 – 2025 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 08: Five forces analysis 2020 & 2025
- 4.2 Bargaining power of buyers
- Exhibit 09: Bargaining power of buyers
- 4.3 Bargaining power of suppliers
- Exhibit 10: Bargaining power of suppliers
- 4.4 Threat of new entrants
- Exhibit 11: Threat of new entrants
- 4.5 Threat of substitutes
- Exhibit 12: Threat of substitutes
- 4.6 Threat of rivalry
- Exhibit 13: Threat of rivalry
- 4.7 Market condition
- Exhibit 14: Market condition – Five forces 2020
5 Market Segmentation by Product
- 5.1 Market segments
- Exhibit 15: Product – Market share 2020-2025 (%)
- 5.2 Comparison by Product
- Exhibit 16: Comparison by Product
- 5.3 Drugs – Market size and forecast 2020-2025
- Exhibit 17: Drugs – Market size and forecast 2020-2025 ($ million)
- Exhibit 18: Drugs – Year-over-year growth 2020-2025 (%)
- 5.4 Devices – Market size and forecast 2020-2025
- Exhibit 19: Devices – Market size and forecast 2020-2025 ($ million)
- Exhibit 20: Devices – Year-over-year growth 2020-2025 (%)
- 5.5 Market opportunity by Product
- Exhibit 21: Market opportunity by Product
6 Market Segmentation by Treatment
- 6.1 Preventive treatment
- 6.2 Abortive treatment
7 Customer landscape
8 Geographic Landscape
- 8.1 Geographic segmentation
- 8.2 Geographic comparison
- 8.3 North America – Market size and forecast 2020-2025
- 8.4 Europe – Market size and forecast 2020-2025
- 8.5 Asia – Market size and forecast 2020-2025
- 8.6 ROW – Market size and forecast 2020-2025
- 8.7 Key leading countries
- 8.8 Market opportunity by geography
9 Drivers, Challenges, and Trends
- 9.1 Market drivers
- 9.2 Market challenges
- 9.3 Market trends
10 Vendor Landscape
- 10.1 Vendor landscape
- 10.2 Landscape disruption
- 10.3 Competitive scenario
11 Vendor Analysis
- 11.1 Vendors covered
- 11.2 Market positioning of vendors
- 11.3 AbbVie Inc.
- 11.4 Amgen Inc.
- 11.5 Eli Lilly and Co.
- 11.6 eNeura Inc.
- 11.7 GlaxoSmithKline Plc
- 11.8 Grunenthal GmbH
- 11.9 H. Lundbeck AS
- 11.10 Pfizer Inc.
- 11.11 Teva Pharmaceutical Industries Ltd.
- 11.12 Upsher-Smith Laboratories LLC
12 Appendix
- 12.1 Scope of the report
- 12.2 Currency conversion rates for US$
- 12.3 Research methodology
- 12.4 List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/migraine-therapeutics-market-report-2021-featuring-major-vendors-including-abbvie-inc-amgen-inc–eli-lilly-and-co–technavio-301585080.html
SOURCE Technavio
Source link
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.
